Back to Search
Start Over
Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine
Early Adverse Events predict Survival Outcomes in HER2-positive Advanced Breast Cancer Patients treated with Lapatinib plus Capecitabine
- Source :
- Journal of Cancer
- Publication Year :
- 2020
- Publisher :
- Ivyspring International Publisher, 2020.
-
Abstract
- Background: This study aimed to investigate the impact of early adverse events (AE) following the initiation of lapatinib plus capecitabine on the progression-free survival (PFS) and overall survival (OS) outcomes of human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer (ABC) patients. Methods: A secondary analysis of participants treated with lapatinib plus capecitabine, or ado-trastuzumab emtansine in the clinical trial EMILIA was conducted. Cox proportional hazard analysis was used to assess the impact of AE occurring within the first 42 days of lapatinib plus capecitabine therapy on the PFS and OS outcomes of ABC patients. Results: The study included 488 HER2-positive (ABC) patients initiated on lapatinib plus capecitabine. Rash (Hazard Ratio (HR) [95% Confidence Interval (CI)]: Grade 1 = 0.67 [0.46-0.98], Grade 2+ = 0.71 [0.42-1.19]; p = 0.046) and hand-foot syndrome (HR [95% CI]: Grade 1 = 0.58 [0.43-0.80], Grade 2+ = 0.61 [0.43-0.86]; p =
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
Nausea
Lapatinib
survival analysis
Capecitabine
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
breast neoplasms
hand-foot syndrome
lapatinib
Adverse effect
skin and connective tissue diseases
Survival analysis
business.industry
capecitabine
Hazard ratio
Rash
adverse events
030104 developmental biology
030220 oncology & carcinogenesis
Vomiting
medicine.symptom
business
medicine.drug
Research Paper
Subjects
Details
- Language :
- English
- ISSN :
- 18379664
- Volume :
- 11
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Journal of Cancer
- Accession number :
- edsair.doi.dedup.....60b08067e80cbb3fa355b5f66216dd6e